Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Shire's sustained-release carbamazepine deemed approvable by FDA

April 4, 1997

Schering-Plough claims adenosine A2a antagonists

April 4, 1997

Novo Nordisk discloses metabotropic glutamate receptor antagonists

April 4, 1997

NeoTherapeutics seeks FDA clearance for AIT-082 clinical trials

April 3, 1997

Teva's Copaxone launched in U.S.

April 3, 1997

Glaxo Wellcome discloses prodrugs of known 5-HT1-like agonist

April 3, 1997

Abbott reveals compounds for controlling synaptic transmission

April 3, 1997

New epilepsy option approved in the U.S.

April 2, 1997

Guilford's neuroimmunophilin ligands covered by U.S. patent

April 2, 1997

Cationized AVP fragment for learning and memory disorders from Yakult

April 2, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...